Factor VIII Activation Antibody for Hemophilia A Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A and related bleeding disorders are limited by the short half-life of Factor VIII preparations, frequent administration requirements, and the presence of inhibitors that can neutralize Factor VIII activity, necessitating the development of a more effective and long-lasting therapeutic solution.
Innovation Solution
The discovery of a monoclonal antibody, moAb216, which enhances the coagulation-enhancing activity of Factor VIII by altering cleavage sites at Arg372 and Arg336, thereby increasing the activity of Factor VIII and its generation, even in the presence of inhibitors, by forming a complex that accelerates activation by thrombin and Factor Xa while decelerating inactivation by APC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Factor VIII preparations are administered to treat hemophilia A, then bleeding symptoms are improved, but the half-life is short requiring frequent administration
Solution Approach 1:
The patent uses a monoclonal antibody (moAb216) as an intermediary that binds to Factor VIII and modifies its cleavage pattern. This antibody-mediated interaction prevents complete inactivation by APC while allowing activation by thrombin and Factor Xa, thereby extending the functional half-life of Factor VIII preparations in hemophilia A treatment
Solution Approach 2:
The invention changes the cleavage parameters of Factor VIII by inducing alternative cleavage at Arg372 instead of the normal Arg336 site. This parameter change in proteolytic processing creates a modified Factor VIIIa that resists APC-mediated inactivation, extending its duration of action while maintaining coagulation efficacy
2Reliability
If Factor VIII is administered frequently to maintain therapeutic levels, then bleeding prevention is improved, but treatment complexity and burden increase
Solution Approach 1:
The monoclonal antibody serves as a mediator that fundamentally alters the kinetic profile of Factor VIII, allowing less frequent administration intervals while maintaining therapeutic efficacy. This reduces the complexity of treatment regimens and patient burden
3Reliability
If high doses of Factor VIII are administered to overcome inhibitors, then coagulation activity is improved, but the risk of inhibitor neutralization increases
Solution Approach 1:
By changing the cleavage parameter from Arg336 to Arg372, the invention creates a Factor VIII variant with altered epitope structure that reduces inhibitor binding affinity. This allows effective coagulation activity at lower doses with reduced neutralization by pre-existing inhibitors in hemophilia A patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MoAb216 increases Factor VIII activity by 1.5-fold, providing a longer half-life and reducing the required dose, effectively treating hemophilia A and other bleeding disorders with minimal interference from existing inhibitors, thus offering a novel replacement therapy.
Implementation Method 1
Factor VIII is converted into activated blood coagulation factor VIII (also referred to as activated blood coagulation factor VIII or Factor VIIIa) by limited proteolysis with thrombin or Factor Xa
Implementation Method 2
The formation of moAb216-Factor VIII complex accelerates the cleavage at Arg372 in the A1-A2 domain junction of Factor VIII by thrombin and Factor Xa
Implementation Method 3
decelerates the cleavage at Arg336 in the A1 domain by APC, which is a representative Factor VIII inactivator
Data Source
AI summary
For the first time, the present invention provides antibodies that enhance the generation of activated blood coagulation factor VIII. The antibodies enhance the cleavage of blood coagulation factor VIII at the Arg of position 372 and suppress the cleavage at the Arg of position 336 by recognizing and binding to the A2 domain of blood coagulation Factor VIII. Such antibodies are expected to be useful in preventing or treating diseases that develop or progress due to decrease or loss of the blood coagulation factor VIII activity, for example, hemophilia A, acquired hemophilia, and von Willebrand's disease.